Blog
Rasonque (Daraxonrasib): Pancreatic Cancer Pill That Doubled Survival Wins European Approval
Europe has approved Rasonque (daraxonrasib), the first broad RAS-targeted pill for metastatic pancreatic cancer. In a Phase 3 trial it doubled median survival versus chemotherapy — 13.2 vs 6.7 months — and delayed pain and quality-of-life decline. What patients should know.